Management of type 2 diabetes in chronic kidney disease

The management of patients with type 2 diabetes and chronic kidney disease (CKD) encompasses lifestyle modifications, glycemic control with individualized HbA1c targets, and cardiovascular disease risk reduction. Metformin and sodium-glucose cotransporter-2 inhibitors are first-line agents. Glucagon...

Descripción completa

Detalles Bibliográficos
Autores principales: Triozzi, Jefferson L, Parker Gregg, L, Virani, Salim S, Navaneethan, Sankar D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Cardiovascular and Metabolic Risk
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8314731/
https://www.ncbi.nlm.nih.gov/pubmed/34312158
http://dx.doi.org/10.1136/bmjdrc-2021-002300

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8314731/
https://www.ncbi.nlm.nih.gov/pubmed/34312158
http://dx.doi.org/10.1136/bmjdrc-2021-002300

Ejemplares similares